Myocarditis: A Rheumatologic Perspective by Mole, Evangelia N et al.
Myocarditis:  
A Rheumatologic Perspective
Evangelia Mole, MD, Vasilios Papadakos, MD, PhD,  
George Katsikas, MD, MSc, Charalampos Sfontouris MD, MSc
A b s t r A c t
Myocarditis is an uncommon complication in patients with autoimmune rheumatic 
diseases. Due to paucity of clinical data, information has mostly been derived from 
postmortem findings. The mechanism of myocardial damage in connective tissue dis-
eases depends on the pathophysiology of the underlying disease. Systemic inflam-
mation, impaired microvascular circulation and vasculitis affect myocardial remod-
eling process, cause repeated focal ischemia resulting in hypertrophy, fibrosis of the 
myocardium and the conductive system, all resulting in reduced contractility. Addi-
tionally, immunological abnormalities, coexisting myositis and the degree of disease 
activity are predictors of myocarditis progression. Clinical presentation ranges from 
subclinical to severe, life-threatening form. Early recognition is important for institu-
tion of appropriate immunomodulatory therapy.
I N t r O D U c t I O N
Myocarditis is an inflammatory reaction of the myocardium to various infectious, 
toxic or autoimmune causes, mainly characterized by inflammatory infiltration and 
cardiomyocyte necrosis.1 The data in the literature about myocarditis in connective 
tissue disorders (CTDs) are limited and most of our knowledge derives from postmor-
tem findings.2 However, it is considered a rare, under-recognized, under-treated and 
potentially fatal complication.5 The mechanism of myocardial damage among CTDs 
differs according to the pathophysiology of the underlying disease. Myocarditis due 
to autoimmune disorders should be urgently recognized because of the likely progres-
sion of the cardiac injury to heart failure or ventricular remodeling with serious and/
or life threatening complications.3 The autoimmune rheumatic diseases that can be 
complicated by myocarditis comprise systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA), anti-neutrophil cytoplasmic antibodies (ANCA)-related vasculitides, 
inflammatory myopathies (IM), systemic scleroderma (SSc) and sarcoidosis. The main 
mechanisms that are involved in myocardial damage in CTDs are systemic inflamma-
tion, microangiopathy and vasculitis (Table 1).4,5 Immunological abnormalities, coexist-
ing myositis and degree of disease activity are additional predictors for the prognosis 
of myocarditis. The above mechanisms affect the myocardial remodeling process by 
causing repeated focal ischemia, resulting in hypertrophy and fibrosis in both myo-
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EGPA = eosinophilic granulomatosis with 
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GPA = granulomatosis with polyangiitis
IM = inflammatory myopathies
LGE = late gadolinium enhancement
LV = left ventric-le(-ular)
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SLE = systemic lupus erythematosus
RA = rheumatoid arthritis
SSc = systemic sclerosis
TGF = transforming or tumor growth factor
TNF = tumor necrosis factor
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cardium, conductive system and thus reduced contractility.5,6
The clinical presentation varies in severity and type of 
symptoms. The spectrum ranges from asymptomatic (subclini-
cal) form to significant, sometimes life-threatening disturbance 
of cardiac function.9 The great heterogenicity in clinical ex-
pression is interpreted according to the location and extent of 
damage.5 However, manifestations range from mild dyspnea 
or chest pain that subside without specific therapy, to sudden 
death, with new onset arrhythmias and complete heart block, 
hemodynamic instability and cardiovascular collapse or an 
acute myocardial infarction-like syndrome. Fatigue and dimin-
ished exercise tolerance, because of low cardiac output, and 
palpitations may also occur.7 Physical findings include a resting 
tachycardia, jugular vein distention, murmurs and diminished 
intensity of the first heart sound.8
The diagnosis of autoimmune myocarditis depends on 
clinical suspicion, because of the lack of definite diagnostic 
tests and a standardized process (Fig. 1). Serum biomarkers of 
myocardial injury, such as creatine kinase or cardiac troponins, 
are routinely measured when myocarditis is suspected, but are 
only helpful early in its course. Creatine kinase or its cardiac 
specific (MB) isoform has low predictive value, while troponins 
have limited sensitivity (34-50%), but high specificity (close to 
90%) for the diagnosis of myocarditis.10 
The electrocardiogram may show sinus tachycardia, ST 
segment and T-wave abnormalities, atrial and ventricular 
arrhythmias, atrioventricular (AV) block and conduction de-
fects.11 The echocardiographic findings, mainly suggesting the 
presence of myocarditis, are left ventricular (LV) segmental 
or global dysfunction and LV dilatation. Right ventricular 
dysfunction is a predictor of adverse outcome.12 Nuclear imag-
ing techniques (gallium and indium-111) lack specificity for 
myocarditis detection.13 Endomyocardial biopsy, an invasive 
technique, is considered the gold standard for the diagnosis 
but it is not routinely performed because of the procedure 
related risks and its limited sensitivity due to sampling error.7 
Cardiovascular magnetic resonance (CMR) imaging enables 
diagnosis of myocarditis by detecting edema, myocyte necrosis, 
fibrosis, changes in ventricular size and wall motion abnormali-
ties.5 CMR detects subclinical forms of disease and allows early 
initiation of targeted therapy.5,7 Early recognition of myocar-
ditis in autoimmune diseases is of great importance because 
its severity specifies the immunomodulatory treatment.9,14
s y s t e m I c  L U p U s  e r y t h e m A t O s U s
Systemic lupus erythematosus (SLE) is a complex auto-
immune, inflammatory multisystem disease characterized by 
immune complex deposition, production of autoantibodies 
and considerable heterogeneity in clinical manifestations, 
laboratory findings and disease outcome. Patients may present 
with any organ system involvement, such as arthritis, serositis, 
skin rash, glomerulonephritis and neurological symptoms.15,17 
Frequent laboratory abnormalities include anemia, leucope-
nia, lymphocytopenia and thrombocytopenia.15,16 Patients may 
have positive antibodies which are directed against various 
nuclear antigens such as nucleosomes, histones, antinuclear 
antibodies (ANA), double-strained DNA antibodies (anti-
dsDNA) and ribonucleoproteins.15,16 The disease incidence is 
higher in young women. A variety of genetic, environmental 
and hormonal factors have been identified as possible risk 
factors for developing SLE. Early diagnosis, intense therapy 
and alternative strategies in treating comorbidities contribute 
to improvement of disease prognosis. 
Lupus myocarditis is infrequent; its overt clinical detection 
ranges from 3-15%, although its frequency in autopsy studies 
is higher, supporting the subclinical presentation of disease.14,18 
In SLE, immune-complex mediated small vessel vasculitis and/
or inflammatory infiltration result in secondary cardiomyocyte 
injury.14 Circulating antibodies may also contribute to this 
process by directly affecting the myocardial tissue. Anticardi-
olipines, anti-Ro and anti-ribonucleoprotein antibodies, are 
associated with left ventricular dysfunction.19,20 Peripheral 
skeletal myositis increases risk for developing myocarditis. 
Acute myocarditis may accompany other manifestations of 
SLE, particularly pericarditis.
Myocardial biopsy was thought to be the gold standard 
method for diagnosis of lupus myocarditis. However, this is 
an invasive procedure associated with certain risks. Histologic 
findings show small foci of fibrinoid necrosis, interstitial mono-
nuclear cell infiltrates, while immunofluoroscence studies 
demonstrate immune complex and complement deposition 
in the walls and perivascular tissues of myocardial vessels, 
tAbLe 1. Mechanisms of Myocardial Damage Among 
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FIGUre 1. Diagnostic algorithm for diagnosing myocarditis in a patient with connective tissue disease (CTD). ACE = angiotensin 
converting enzyme; ANA = antinuclear antibodies; ANCA = anti-neutrophil cytoplasmic antibodies; AV = atrioventricular; BNP 
= brain natriuretic peptide; CCP = cyclic citrullinated peptide; CHF = congestive heart failure; CK MB = creatine kinase isoform 
MB; CMR = cardiac magnetic resonance; CRP = C-reactive protein; cTn = cardiac troponin(s); DNA = deoxyribonucleic acid; 
dsDNA = double stranded DNA; ECG = electrocardiogram; ECHO = echocardiography; EMB = endomyocardial biopsy; ESR 
= erythrocyte sedimentation rate; LV = left ventric-le(-ular); LVEF = left ventricular ejection fraction; RF = rheumatoid factor; 
R/O = rule out
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supporting the theory that lupus myocarditis is an immune 
complex mediated vascular disorder.21,22
Myocarditis may present as fever, dyspnea, palpitations, 
non-exertional chest pain with resting tachycardia, jugular 
venous distention, peripheral edema and new onset cardiac 
murmurs.23 Myocarditis should be suspected in patients who 
present with new onset arrhythmias (sinus tachycardia) or 
conduction defects.6,23 Despite the fact that conduction defects 
are rare in adult patients with SLE, infants born to mothers 
with positive anti-Ro and anti-La antibodies have increased 
incidence of congenital complete AV block.9 Probably myo-
cardial inflammation and fibrosis of the conduction system is 
caused by the transplacental passage of these antibodies to 
the fetus.6,9 Further studies should be done in order to prove 
if this antibody has a direct arrhythmogenic effect. If lupus 
myocarditis remains uncontrolled, progression to dilated 
cardiomyopathy and chronic heart failure may occur.19
The diagnosis of lupus myocarditis is based on clinical 
suspicion. The electrocardiogram reveals non-specific ST-T 
wave changes, conduction defects, premature atrial or ven-
tricular beats and ventricular or supraventricular tachycardia.24 
There is echocardiographic evidence of segmental or global 
wall motion abnormality, accompanied by reduced LV systolic 
function (LV ejection fraction), pericardial effusion and pul-
monary hypertension. Cardiac magnetic resonance (CMR) is 
a non invasive technique sensitive to changes that characterize 
lupus myocarditis.25 CMR provides information about edema, 
increased capillary leakage and focal necrosis of cardiac mus-
cle. Increased T2-weighted signal is a sensitive indicator of 
myocardial disease during the acute phase of inflammation, 
as a result of edema presence, even in the absence of clinically 
overt myocardial involvement.14 Extensive subendocardial late 
gadolinium enhancement (LGE) images represent myocardial 
fibrosis, which is associated with chronic inflammation rather 
than active acute myocarditis.14
As there is no single treatment for SLE, appropriate ther-
apy should be individualized and selected according with the 
severity of disease manifestations. Immunosuppressants may 
be introduced for treatment of lupus myocarditis, in order to 
improve systolic heart function. Severe forms of disease should 
be treated with intravenous pulses of methylprednisolone for 
three days, followed by intravenously or orally administrated 
prednisone (1 mg/kg/d) with gradual tapering. Other im-
munosuppressants, such as cyclophosphamide, azathioprine, 
mycophenolate mofetil, should also be added.9,19 Some case 
reports revealed the beneficial role of intravenous gamma 
globulin usage in steroid-refractory lupus myocarditis cases.26 
Furthermore, supportive therapy for LV dysfunction, includ-
ing angiotensin converting enzyme inhibitors, diuretics and 
β-adrenergic blocking agents, should be added in all patients.19 
During the follow up period, echocardiographic findings in 
most patients get improved, while a big percentage of patients 
show reversal of myocardial damage in a period of 6 months 
following immunomodulatory treatment.27 Mortality rates are 
higher in clinically overt myocarditis than in the subclinical 
form. In general, development of myocarditis in SLE reflects 
worse overall disease activity.23 
r h e U m A t O I D  A r t h r I t I s
Rheumatoid arthritis (RA) is a common autoimmune, 
inflammatory disorder that affects almost 1% of the adult 
population.29 The disease has a female predominance and its 
peak onset is during their third to fifth decade of life.9 RA typi-
cally presents with symmetrical polyarthritis of small and large 
joints, accompanied by variable in duration morning stiffness 
and by presence of autoantibodies particularly to rheumatoid 
factors and citrullinated peptides.28 A positive rheumatoid fac-
tor does not confirm the diagnosis of RA, as it may be present 
in healthy individuals and in a variety of other diseases. The 
anti-cyclic citrullinated peptide test offers some specificity to 
the serologic diagnosis.28 However, the RA diagnosis is based 
on clinical presentation. Seropositive RA patients present 
with more severe disease and extra-articular manifestations. 
Myocarditis in RA is a rare complication, that seldom 
becomes clinically apparent.9 Higher RA disease activity is 
associated with increased myocarditis incidence. Inflammatory 
infiltration of the myocardium and the conductive system is 
the main mechanism of developing myocarditis.5 Two different 
histological patterns of RA myocarditis have been described. 
The non-specific form, which can also be observed in other 
disorders, is characterized by presence of an infiltrate that 
might be composed of lymphocytes, plasma cells, histiocytes 
and involves the collagenous interstitium of the heart. The 
granulomatous form is considered as the specific type for RA 
myocarditis. Granulomas are usually formed in seropositive 
RA patients, morphologically are identical to subcutaneous 
rheumatoid nodules and they usually appear in the left ven-
tricle.29 These two forms of RA myocarditis are implicated in 
the pathogenesis of arrhythmias, conduction disorders and 
secondary dilated cardiomyopathy resulting in heart failure 
with severe diastolic impairment.9,29 
Symptoms of RA myocarditis are usually subtle, and 
when they become clinically apparent are associated with 
advanced heart failure. Clinical presentation of myocarditis 
includes fatigue, mild dyspnea or chest pain and palpitations. 
During early stages, myocarditis is undetectable with the 
everyday used imaging techniques, such as echocardiography 
or scintigraphy.29 The electrocardiogram may show sinus 
tachycardia, T waves abnormalities and conduction defects.7 
Echocardiography in RA myocarditis reveals LV diastolic 
dysfunction, such as increased left atrial volume, enlarged left 
atria size, alternations in E/A wave ratio and elevated systolic 
pulmonary artery pressures.30 CMR, is the ideal technique 
for diagnosis of myocarditis. T2-weighted images detect pres-
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ence of edema, which is apparent when active inflammation 
is present. High levels of early myocardial enhancement after 
gadolinium administration are due to increased membrane 
permeability. Late gadolinium enhanced images detect myo-
cardial necrosis occurring in RA.29 The pattern of lesions is 
mainly intra-myocardial or subepicardial, can be found at any 
area of myocardium and is independent of the distribution of 
coronary vessels. Finally, CMR offers the opportunity to detect 
silent (subclinical) myocardial involvement in RA patient.31 
In general, higher disease activity, long lasting disease and 
extra-articular manifestations are strongly associated with in-
creased myocarditis incidence.29 Because of the rarity of rheu-
matoid myocarditis, optimal treatment is uncertain. As initial 
therapy, usage of high dose methylprednisolone (pulse therapy 
500-1000 mg/day for 3 days, or 80 mg/day) is usually suggested. 
Reduction of RA systemic manifestations, including myocar-
ditis, is evaluated by early introduction of therapy with disease 
modifying drugs. Traditional disease-modifying antirheumatic 
drugs that may be used as monotherapy or in combination are 
methotrexate (up to 25 mg/week), sulfasalazine (up to 3 g/
day), leflunomide (20 mg/day) and hydroxychloroquine (400 
mg/day). Aggressive control of systemic inflammation of RA 
with methotrexate or anti-tumor necrosis factor (TNF) agents 
may reduce cardiovascular morbidity.9 Recent studies showed 
that treatment with anti-TNF agents or interleucin-6 inhibi-
tion agents led to improvement of diastolic function within a 
follow-up period of 6-12 months.32 However, administration 
of anti-TNF agents in patients with severe heart failure (New 
york Heart Association functional class III-IV) should be 
avoided because of increased cardiac mortality.33 Supportive 
treatment for improvement of LV dysfunction caused by RA 
myocarditis, such as angiotensin converting enzyme inhibitors, 
or angiotensin-receptor blockers, diuretics and β-adrenergic 
blocking agents, is commonly suggested.29
s y s t e m I c  s c L e r O s I s
Systemic sclerosis or systemic scleroderma (SSc) is a 
CTD characterized by microangiopathy and tissue fibrosis.34 
Involvement of vascular system results in development of 
Raynaud’s phenomenon early in the disease course. Deposi-
tion and overproduction of extracellular matrix proteins and 
collagen result in tissue fibrosis and dysfunction. Several 
growth factors such as transforming or tumor growth factor 
(TGF)-β and endothelin-1 are involved in tissue remodeling, 
whereas vasospasm causes repeated focal ischemia.5 Systemic 
scleroderma is a rare disease, with incidence 0.6 to 19 per 
million of general population per year. Disease has a female 
predominance and occurs between 45 and 65 years of life. It 
is divided into limited cutaneous and diffuse/systemic form. 
Almost all patients with SSc or CREST (calcinosis, Raynaud 
phenomenon, esophageal dysmotility, sclerodactyly, and 
telangiectasia) syndrome have positive ANA, while anti-
topoisomerase antibodies (anti-SCL 70) may be also positive 
in SSc patients.9 
SSc patients with long lasting Raynaud phenomenon, coex-
isting myositis and positive anti-ribonucleoprotein antibodies 
are more prone to develop myocarditis, which usually has a 
subclinical course and sometimes can be underestimated.1 
When clinically apparent, primary myocardial involvement is 
considered as an important prognostic factor for disease out-
come.38 Multiple causes can lead to myocarditis pathogenesis. 
Myocardial damage in SSc is much more common in patients 
with diffuse disease and/or coexisting peripheral skeletal my-
ositis.9 A mild but persistent increase in creatine kinase-MB 
and/or troponin levels refers to possible myocarditis. Besides 
skeletal myositis, pericardial effusion should always be counted 
as a red flag for identification of myocardial inflammation.39 
Additional factors, such as early disease, ventricular ectopic 
beats, wall motion abnormalities, ANCA positivity, myositis 
and pericardial effusion should be evaluated. ANCA anti-
bodies are uncommon in SSc, however a correlation between 
C-ANCA/PR3 positivity and SSc myocarditis was found in 
some studies.40
Myocardial biopsy may increase the frequency of detection 
of myocarditis. However, the procedure is rarely indicated be-
cause of its invasive nature and high rate of sampling errors.41 
Myocardial biopsies show fibrotic changes in endocardial 
and subendocardial layer, severe interstitial fibrosis, prolif-
erating myofibroblasts and patchy infiltrations composed of 
macrophages and activated T-helper lymphocytes.9,36 Clinical 
presentation of myocarditis in SSc may include chest pain, 
palpitations, shortness of breath and signs of heart failure 
unrelated to lung disease progression. Conduction defects are 
frequently observed in the electrocardiogram of asymptomatic 
patients.6 Premature ventricular contractions and monomor-
phic tachycardias are the most common arrhythmias in SSc.37 
Clinically overt SSc myocarditis makes prognosis worse and 
leads to sudden death.6,9 Coexistent peripheral skeletal myositis 
is associated with increased risk for heart failure and mortality. 
The electrocardiographic findings of SSc myocarditis 
include supraventricular tachycardia, conduction defects 
and ST-segment abnormalities.35,36 Echocardiography, shows 
segmental or global LV dysfunction, decreased ejection frac-
tion, diastolic and systolic dysfunction with E/A ratio <1 and 
sometimes pericardial effusion.36,38 Angiographic studies reveal 
normal coronary arteries, supporting the theory of impaired 
microvasculature in the pathogenesis of myocarditis in SSc.9,36 
Cardiac magnetic resonance is a useful modality for accu-
rately detecting fibrotic myocardium in SSc. Late gadolinium 
enhancement imaging can identify myocardial fibrosis in 66% 
of SSc patients.37 Myocardial fibrosis has a linear pattern and 
is limited to the midwall layer, with invariable sparing of the 
subendocardium and epicardium.37 It has a non-coronary 
distribution, predominantly located in the basal and midcavity 
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segments of the left ventricle. Increased signal T2-weighted 
images, are also observed in SSc myocarditis cases.35 CMR also 
provides the means for monitoring the effects of treatment 
and thus prevents deterioration of heart disease. Several stud-
ies revealed an association between arrhythmias and degree 
of fibrosis.6 However, myocardial fibrosis detected by CMR 
may occur concurrently or independently of fibrosis of other 
internal organs and may not be associated with the extent of 
skin involvement.42
Recognition of myocarditis determines the therapeutic 
implications. The goal of immunosuppression is clinical 
improvement, normalization of cardiac enzymes and CMR 
stabilization. Best therapeutic results are obtained in patients 
with lower degrees of fibrosis.36 To date there is no proven 
effective therapy that can limit the progression of SSc, and 
the target remains to control the symptoms. Long-term high 
doses of glucocorticoids should be cautiously used because 
they do not control heart failure and they increase the risk of 
developing scleroderma renal crisis.9 We usually administer 0.5 
mg/kg/day of prednisone, followed by 5-mg dose tapering every 
10 days, while the lowest possible effective dose that should 
be used remains preferably below 20 mg/day. Corticosteroids 
may control the inflammatory process but not the subsequent 
heart failure.43
Further immunomodulatory treatment includes cyclophos-
phamide (2 mg/kg/day up to cumulative dose of 6 g), followed 
by azathioprine (2 mg/kg/day). In refractory cases rituximab 
in combination with cyclophosphamide has been tried and 
further deterioration of cardiac function was prevented.35 
Patients progressing to heart failure should be also controlled 
with diuretics, angiotensin converting enzyme inhibitors and 
aspirin (100 mg/day). Amiodarone controls ventricular ar-
rhythmias.9 Vasodilatory therapy with calcium-channel block-
ers, prostacycline or endothelin antagonist may be associated 
with improvement in intimal proliferation. 
Myocarditis is a major predictor of increased mortality 
in SSc, hence early diagnosis and induction therapy is crucial 
for modifying the disease course, by leading to significant 
clinical improvement, normalization of cardiac enzymes and 
regression or stabilization of CMR in the majority of cases.36,37 
I N F L A m m A t O r y  m y O p A t h I e s
Autoimmune inflammatory myopathies (IM), namely 
dermatomyositis (DM) and polymyositis (PM) are chronic 
inflammatory muscle diseases that share common clinical 
features, such as proximal muscle weakness, elevated levels 
of muscle enzymes, electromyographic alterations, presence 
of autoantibodies, histopathological evidence of inflammatory 
infiltrations in skeletal muscles and extramuscular manifesta-
tions.44 Extramuscular involvement, such as the skin in DM, 
interstitial lung disease, arthritis, gastrointestinal involvement 
(dysphagia), Raynaud phenomenon and photosensitivity, is 
common. DM is associated with skin involvement (heliotrope 
rash, Gottron’s papules and sign). Both entities are associated 
with increased incidence of neoplasms. When extramuscular 
manifestations, such as interstitial lung disease and cardiac 
involvement are present, the survival prognosis is getting 
worse.46 Despite clinical similarities, certain histopathological 
findings help to distinguish these disorders from each other 
and reflect their distinct pathophysiologic pathways. 
Autoantibodies are frequently detected in patients with 
inflammatory myopathies. Antinuclear antibodies may be 
present in 80% of patients with DM or PM. Antisynthetase 
antibodies are myositis specific antibodies. The most fre-
quently observed is anti-Jo1 antibody, which is directed against 
histidyl-tRNA synthetase and is seen in about 20% of patients 
with idiopathic inflammatory myositis.47 Anti-Jo1 antibodies 
are strongly associated with several clinical findings, including 
interstitial lung disease, Raynaud’s phenomenon, arthritis and 
mechanic hands. Other myositis specific antibodies, but less 
commonly detected, are anti-Mi-2 and anti-signal-recognition 
peptide autoantibodies.48
Myocarditis in IM is caused by direct inflammation of the 
heart muscle.5 The incidence of clinical myocardial involve-
ment in these conditions is rather low.44 Myocarditis usually 
occurs simultaneously with skeletal muscle inflammation, but 
it may also develop even in patients with low disease activity. 
Histopathological findings resemble those of skeletal muscle 
inflammation. Infiltrations are composed of mononuclear 
inflammatory cells, localized in the endomysium and the 
perivascular areas with degeneration of cardiomyocytes.49 
Similar histopathological findings are also observed in the 
conducting system, including lymphocytic infiltrates, fibrosis 
of sinoatrial node and contraction band necrosis.45
The symptomatic form of cardiac involvement with his-
tologic evidence of myocarditis in IM, including clinically 
evident congestive heart failure with impaired LV function, 
is relatively uncommon.45 Other clinical symptoms, such as 
palpitations, shortness of breath, non-productive cough, chest 
pain and syncope have been described. Physical examina-
tion may reveal signs of jugular venous distention, wheez-
ing, rhonchi at the lower lung fields and peripheral edema. 
Techniques such as electrocardiography (ECG), Holter 
monitoring, echocardiography, myocardial scintigraphy have 
poor sensitivity and specificity for detecting subclinical heart 
abnormalities.44 Arrhythmias and conduction defects detected 
by electrocardiographic studies are frequently reported. Atrial 
and ventricular arrhythmias, bundle branch block, AV block, 
atrial and ventricular premature beats, abnormal Q waves and 
non specific ST-T wave changes can be found in ECG and 
Holter monitoring.44
Echocardiography reveals segmental or global hypokinesia, 
septal and LV hypertrophy resulting in diastolic dysfunction.50 
Nuclear imaging techniques lack sensitivity and specificity 
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for detecting myocarditis in IM. CMR LGE imaging proved 
more sensitive to detect affected parts of the myocardium in 
inflammatory myopathies than conventional laboratory tests 
(creatine kinase, C-reactive protein, erythrocyte sedimenta-
tion rate, cardiac troponins).51 Increased LGE intensity signal 
is usually observed in the left ventricle. LGE imaging is also 
sensitive in detecting changes of myocardium following im-
munomodulatory therapy.7 Cardiac troponins are a reliable 
marker with highest specificity for detection of myocardial 
involvement in patients with inflammatory myocardial dam-
age,45 compared to creatinine kinase isoenzyme MB.44 
Treatment of myocarditis in IM is usually empirical. The 
effects of glucocorticoids and immunosuppressants on cardiac 
manifestations are conflicting, since some cases of congestive 
heart failure get improved and some others deteriorate. Some 
studies revealed that myocarditis occurrence is independent 
of steroid therapy and disease activity.49 There are some case 
reports suggesting that rituximab has good results in manage-
ment of myocarditis.52 Besides immunosuppressive therapy, 
patients experiencing symptoms of congestive heart failure, 
should be treated with medications such as nitrates, β-blockers, 
angiotensin converting enzyme inhibitors and diuretics. There 
are few reports of patients with complete heart block that have 
been treated with a pacemaker, and fewer reports of patients 
successfully transplanted for dilated cardiomyopathy.45
s y s t e m I c  v A s c U L I t I D e s
c h U r G  s t r A U s s  s y N D r O m e / e O s I N O p h I L I c 
G r A N U L O m A t O s I s  w I t h  p O Ly A N G I I t I s  ( e G pA )
Primary systemic vasculitides are inflammatory necrotizing 
diseases of unknown etiology, whose differentiation depends 
upon the vessel size and the organ affected. Churg Strauss 
syndrome (CSS) is a rare systemic vasculitis of small and 
medium - sized vessels, frequently involving the lung, skin, pe-
ripheral nerves, kidneys, heart and is associated with peripheral 
eosinophilia (>10% eosinophils).53 EGPA occurs primarily in 
patients with a previous history of allergic rhinitis and adult 
onset asthma (>95% of cases). The incidence of EGPA is ap-
proximately 2.4 cases/1000000 persons, it may affect any age 
and gender. In general, the prognosis of EGPA is good, with 
overall 10-year survival rate of 81-92%.
Clinical features of EGPA typically develop in three phases 
that may appear simultaneously. The prodromal phase consists 
of asthma and allergic manifestations. The second phase is 
characterized by peripheral blood and tissue eosinophilia in 
the lungs and the myocardium and finally the systemic phase, 
which is accompanied by life – threatening necrotizing vasculi-
tis. Involvement of the myocardium has been described in the 
third phase as a vasculitic lesion in heart tissue.57 EGPA is di-
agnosed on the basis of clinical and histopathological features. 
ANCA antibodies are found in 40-60% of patients with CSS. 
These are directed against myeloperoxidase with perinuclear 
staining pattern.57 ANCA – positive patients experience neuro-
logic and renal manifestations, while cardiac involvement has 
been associated with absence of ANCA antibodies.59 
Eosinophilic myocarditis is one of the most common forms 
of cardiac involvement in patients with CSS.54 Eosinophilic 
myocarditis may be clinically expressed as acute myocardial 
infarction, accompanied by ECG changes, elevated levels of 
cardiac enzymes (creatine kinase MB, troponin), hypertrophy 
of left ventricle in echocardiography, while coronary angiog-
raphy excludes acute myocardial infarction. The differential 
diagnosis of eosinophilic myocarditis includes other types of 
myocarditis that are characterized by myocardial eosinophilic 
infiltration and may occur in the course of hypereosinophilic 
syndromes. Myocardial damage occurs more often by direct 
eosinophilic infiltration, resulting in fibrosis and less often it 
follows the model of systemic vasculitis.54 In some cases, myo-
cardial granulomas are also observed.9 Myocardial involvement 
is an important prognostic factor in the “five factor score” for 
EGPA, associated with increased rates of mortality, so early 
diagnosis is of great clinical importance.56 
unfortunately due to its subclinical course, myocarditis 
might be underdiagnosed. However, when it is clinically ap-
parent, symptoms such as chest pain, shortness of breath and 
palpitations may be present. Myocarditis seems to be highly 
prevalent among EGPA patients in remission, so an adequate 
evaluation plan should be designed in order to eliminate 
irreversible changes by inducing appropriate therapy.57 Elec-
trocardiographic changes include right or left bundle branch 
block, ST–T waves abnormalities, ventricular arrhythmias, 
pathologic Q waves and conduction defects.57 Pericardial ef-
fusion, wall motion abnormalities, valvular insufficiency due 
to fibrosis, LV diastolic dysfunction and/or impaired systolic 
function are findings of echocardiography. Diastolic dysfunc-
tion can be related to increased myocardial stiffness caused 
by inflammatory process and fibrotic lesions.56
Coronary angiography is usually normal, suggesting 
predominant involvement of smaller vessels in EGPA myo-
carditis.54,57 Cardiac magnetic resonance has been successfully 
used for the evaluation of myocardial inflammation, even in 
subclinical forms of disease with low inflammatory indexes. 
The typical CMR pattern includes patchy myocardial edema 
that may be smaller than myocardial scarring.60 Scar has the 
form of diffuse subendocardial LGE, while an epicardial and 
intramyocardial pattern can be also present.7,59 The patients 
with higher number of segments affected on LGE usually 
demonstrate a decreased LV ejection fraction (<50%), posi-
tive ECG stress test and ventricular arrhythmias on Holter 
monitoring.56 Signs of acute ongoing inflammation, such as 
edema with increased T2 weighted imaging, hyperemia and 
increased capillary leakage detected by early gadolinium en-
hancement can be present.56,59 Peak eosinophilia, before the 
initiation of corticosteroid therapy is associated with presence 
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of systolic heart failure and rhythm disturbances. In EGPA 
ANCA antibodies correlate negatively with heart involvement. 
Elevated levels of cardiac enzymes are also observed.
Early diagnosis of myocarditis in EGPA and selection of 
appropriate therapy can prevent progression and improve 
prognosis. Acute onset disease should be treated with intrave-
nous pulses of glucocorticoids (methylprednisolone 1 g/day for 
3 days) followed by oral glucocorticoid therapy.55 Administra-
tion of prednisone (0.5-1 mg/kg/day) is required until clinical 
remission is obtained.54 Gradual tapering of corticosteroids to 
the lowest dose is required for control of symptoms and signs 
of active disease. Further addition of immunosuppressive 
therapy is recommended for EGPA myocarditis, in order to 
achieve lower mortality rates. Cyclophosphamide can be ad-
ministered orally every day or intravenously every month, for 
6 to12 months. Different studies revealed that more episodes 
of myocarditis relapse occurred when 6 pulses of cyclophos-
phamide were used in contrast to 12 pulses. 55 Azathioprine 
is further used as maintenance therapy.59 In general, immedi-
ate therapy allows recovery of cardiac function and reduces 
mortality associated with EGPA.55
w e G e N e r  G r A N U L O m A t O s I s /
G r A N U L O m A t O s I s  w I t h  p O Ly A N G I I t I s  ( G pA )
Wegener granulomatosis is a multisystem disease of un-
known etiology, characterized by granulomatous inflammation, 
tissue necrosis and variable degrees of vasculitis in small and 
medium – sized blood vessels. Although GPA may affect any 
organ system, the disease has a predilection for the upper 
respiratory tract, lungs and kidneys.61 The renal manifestation, 
a pauci – immune glomerulonephritis, is often associated with 
rapidly progressive renal dysfunction. Wegener granulomatosis 
can be generalized when all three major anatomic sites are 
affected and limited in the absence of renal involvement. The 
annual incidence of GPA is at least 8.5 cases per million of 
people, males and females are equally affected and the mean 
age of diagnosis is the fourth decade of life.
The majority of GPA cases and particularly those with 
severe widespread disease are strongly associated with the 
presence of cytoplasmic anti-neutrophil cytoplasmic antibodies 
(c-ANCA) with specificity against proteinase-3 (anti-PR3).62 
Only 10% of patients with GPA have positive perinuclear 
(p)-ANCA, with anti-myeloperoxidase pattern, while 10-20% 
of patients with active – untreated GPA are ANCA negative, 
suggesting that a negative ANCA assay does not preclude the 
diagnosis of GPA.64 Overall, ANCA titers correlate with GPA 
activity in 60% of cases. A rise in ANCA titer or a transition 
from negative to positive in patients with clinically inactive 
GPA heralds exacerbation of disease.58
Although clinically overt myocarditis in GPA is rare, there 
is growing evidence of subclinical myocardial involvement dur-
ing the course of the disease, associated with poor prognosis. 
Myocardial involvement is usually caused by inflammatory 
infiltration of cardiomyocyte and vessel wall, progressing 
to cardiomyopathy with impaired diastolic function.62 High 
prevalence of myocarditis reflects increased disease activity 
and resistance to therapy, and it is recognized as a predictor 
of relapse. Clinical presentation ranges from mild dyspnea, 
chest pain and palpitations to sudden death with new onset 
supraventricular arrhythmias and complete heart block.63 
Endomyocardial biopsy, used for diagnosis of GPA myocar-
ditis, has a poor diagnostic accuracy due to patchy myocardial 
involvement.62
The electrocardiogram and echocardiography are the most 
often used screening tools for evaluation of myocardial involve-
ment in GPA. In the subclinical form, the above techniques can 
be normal. The ECG may show sinus tachycardia, ventricular 
arrhythmias and conduction defects.58 Echocardiography may 
reveal diastolic dysfunction with segmental wall abnormalities, 
LV dilatation and decreased LV ejection fraction (<50%).58,62 
CMR appears to be a sensitive noninvasive diagnostic tech-
nique to assess myocardial involvement in GPA, even in the 
subclinical form of the disease. Combination of T2 - weighted 
and LGE images can define the presence, acuity and extent of 
myocardial involvement in course of GPA, by distinguishing 
acute from chronic inflammation. T2 - weighted images detect 
myocardial edema, which corresponds to acute inflammation 
phase, and LGE images detect fibrosis. Most of lesions de-
tected by CMR - LGE imaging are located in the left ventricle 
and are usually distributed as patchy lesions in all myocardial 
layers (subendocardial, midwall, subepicardial).58
Treatment for myocarditis should be individualized accord-
ing to GPA disease activity and severity. Common regimens 
used are intravenous pulses of methylprednisolone, followed 
by daily prednisone (1 mg/kg/day) and subsequent tapering 
with goal to reach 10 mg/day. Cyclophosphamide is adminis-
tered in dose of 1.5 mg/kg/day every 4 weeks for 6 months.59,62 
Azathioprine can be used as a maintenance therapy in dose 
of 2 mg/kg daily.62 When the above regimens fail to achieve 
disease control or relapses occur, rituximab should be used. 
The efficacy and safety effect of rituximab is similar to that 
of cyclophosphamide.65 Several studies have demonstrated 
regression of myocarditis CMR findings after treatment with 
corticosteroids, cyclophosphamide and rituximab.66 
s A r c O I D O s I s
Sarcoidosis is a rare systemic, non-caseating granuloma-
tous disease of unknown etiology that classically involves lungs, 
but can affect any organ within the body, including the heart.67 
Sarcoidosis typically affects young people. An antigen – driven 
cell mediated immune response is thought to be implicated in 
disease pathogenesis. Antigens processed by antigen present-
ing cells, bear human leucocyte antigen (HLA) class II, that are 
then recognized by CD4 + T cells, leading to an augmented 
immune response, persistent inflammation, non-caseating 
granuloma formation, potential fibrosis of involved organs 
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and variations in clinical presentation and severity of illness. 
Sarcoidosis may typically present with one or more of the 
following abnormalities, such as bilateral hilar adenopathy, 
pulmonary reticular opacities, skin, joint and eye lesions. 
Cardiac sarcoidosis can be a benign, incidentally discovered 
condition or a life threatening disorder. Several autopsy stud-
ies established an incidence of myocardial involvement in 20 
to 50% of cases, while only a small proportion of them (5%) 
become symptomatic, influencing the prognosis and mortality 
rates.67 Inflammatory infiltration of myocardium is the main 
mechanism leading to sarcoid myocarditis.69 Sarcoid myocar-
ditis may be detected alone, may precede, follow or occur 
concurrently with other organ involvement, for example lung 
involvement. Endomyocardial biopsy is essential for diagnosis 
of sarcoid myocarditis. However, the procedure has limited 
sensitivity because of its invasive nature and the high rate of 
false negative results secondary to patchy distribution of myo-
cardial infiltrartion.70 Histology reveals small non-caseating 
granulomas with extensive fibrosis and segmental myocardial 
distribution.68 Myocardial granulomas predominantly affect 
the basal and lateral LV septum, papillary muscles and right 
atrium.70
The signs and symptoms of sarcoid myocarditis depend 
upon the location and extent of granulomatous inflamma-
tion. Sarcoid myocarditis usually presents with conduction 
abnormalities, ventricular and atrial arrhythmias, pericardial 
effusion and can progress to refractory congestive heart failure 
and sudden death.67 Complete heart block is the most common 
finding in patients with clinically evident cardiac sarcoidosis.68 
Heart failure with diastolic and systolic dysfunction can occur 
when there is extensive granulomatous infiltration of myocar-
dium. The diagnosis is a great challenge, frequently missed or 
delayed, especially when the disease remains asymptomatic. 
The electrocardiogram detects arrhythmias, conduction de-
fects or repolarization abnormalities, such as premature 
ventricular beats, ventricular tachycardia, right bundle branch 
block, axis deviation or AV block.68
Echocardiographic findings include abnormalities such as 
LV dilatation, septal thinning, segmental or global hypokinesia 
of the left ventricle, ventricular aneurysms (usually apical), 
valvular regurgitation, mitral valve prolapse secondary to 
papillary muscle dysfunction, and/or right ventricular dilatation 
and hypokinesis.71 Sarcoid lesions may also cause an increase 
in myocardial wall thickness, simulating LV hypertrophy, or 
increased interventricular septal thickness, resembling hyper-
trophic cardiomyopathy. The regional wall motion abnormali-
ties are independent of coronary vessel distribution. 
Cardiac magnetic resonance is the technique of choice in 
the evaluation of sarcoid myocarditis, as it enables a nonin-
vasive and accurate diagnosis. Increased T2-weighted signal 
intensity and early gadolinium enhancement imaging detect 
edema, a sign of acute inflammation.69 T1-weighted images 
illustrate wall motion abnormalities, hypertrophy due to pos-
sible infiltrative disease, wall thinning or heart failure. LGE 
imaging assesses fibrosis or scar and represents chronic phase 
of disease. In case of sarcoid myocarditis, LGE shows diffuse 
or focal enhancement in the mid-myocardial or subepicardial 
region independently of coronary vessel distribution.7,72 Differ-
ent studies revealed that CMR LGE imaging has a prognostic 
value for sarcoid myocarditis, by providing information for 
future potential lethal events including death.5,72 Coronary 
angiography is usually normal, as sarcoidosis, rarely involves 
coronary vessels. Typical presentation with complete heart 
block, elevated serum angiotensin converting enzyme and typi-
cal histologic and CMR findings are crucial for the diagnosis 
of myocarditis.
Treatment of sarcoid myocarditis aims to control the 
inflammation, prevent fibrosis and further compromise of 
cardiac structure or function. Patients usually respond well 
to steroids, rather than to therapy for acute heart failure. 
Steroids are capable of slowing the progression of inflam-
mation and fibrosis and of preventing further LV function 
deterioration.69,73 The optimal dose of corticosteroids is not 
known. Several cohort studies have shown benefits of oral 
prednisone at doses 30-60 mg/day for 8-12 weeks with gradual 
tapering to the dose of 10-20 mg/day over 6 months.73 Gluco-
corticoid treatment should be continued for at least one to two 
years, and dosage should always be adjusted because of side 
effects. Relapses of sarcoid myocarditis should be handled by 
reinstituting prednisone at 30-60 mg/day. Patients that cannot 
respond to glucocorticoids or cannot tolerate the drug because 
of side effects, alternative agents such as hydroxychloroquine 
or cyclosporine may be used, depending on patient and disease 
severity. Since incidence of sudden death due to ventricular 
tachyarrhythmias or conduction defects is high, an implant-
able cardioverter defibrillator is sometimes recommended.74 
Patients with symptomatic sarcoid myocarditis and coexisting 
pulmonary involvement have decreased overall survival.
c O N c L U s I O N
Myocardial involvement in autoimmune rheumatic dis-
eases is the consequence of various pathologic alterations in 
immune processes that result in impaired heart contractility 
or conduction system disease. Prompt diagnosis of myocarditis 
is of great importance for the selection of proper immunosup-
pression therapy, so that reversal of myocardial dysfunction 
can be achieved. Cooperation among rheumatologists and 
cardiologists is required for a better disease outcome.
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